Skip to main content
NewslettersWatchlist

Atyr Pharma Inc(LIFE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.5800
Day High1.6400
Open:1.6000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Globe Newswire
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis
AccessWire
Love Hemp Group PLC Announces Directorate Changes and Trading Suspension Update
Globe Newswire
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Globe Newswire
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
Globe Newswire
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
Globe Newswire
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AccessWire
Love Hemp Group PLC Announces Update to Announcement of 9 May 2022
AccessWire
Love Hemp Group PLC Announces Update Regarding Trading Suspension
AccessWire
Love Hemp Group PLC Announces Update Regarding Suspension & Feb 2022 Fundraise
Globe Newswire
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
Globe Newswire
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
Globe Newswire
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
AccessWire
Love Hemp Group PLC Announces Result of General Meeting
Globe Newswire
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
AccessWire
Love Hemp Group PLC Announces Response to the Latest FSA Novel Foods Update
Globe Newswire
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
Globe Newswire
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Globe Newswire
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Globe Newswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results
AccessWire
Love Hemp Group PLC Announces Request to Requisition General Meeting
AccessWire
Love Hemp Group PLC Announces Love Hemp Scoops Awards for its CBD Products
AccessWire
Love Hemp Group PLC Announces Total Voting Rights
Globe Newswire
aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day®
AccessWire
Love Hemp Group PLC Announces Directorate Change and Issue of Shares for Debt
AccessWire
Love Hemp – First CBD Brand to Launch on eBay UK
AccessWire
Love Hemp Group PLC Announces Deliveroo Update
AccessWire
Love Hemp Group PLC Announces Result of Fundraise
Globe Newswire
aTyr Pharma to Present at BIO CEO & Investor Conference
AccessWire
Love Hemp Group PLC Announces Corporate Update, Fundraise & Result of GM
AccessWire
Love Hemp Group PLC Announces Directorate Changes
Globe Newswire
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Profile

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.